RETRACTION: Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway (Retraction of Vol 33, Pg 840, 2015)

Quan Chen,Ping Li,Yong Xu,Yang Li,Bo Tang
DOI: https://doi.org/10.3892/or.2023.8505
2023-01-01
Oncology Reports
Abstract:Subsequent to the publication of the above article, a concerned reader drew to our attention that the flow cytometric plots shown in Fig. 2 had previously appeared in another article published in the journal Oncology Reports [Huang G, Tang B, Tang K, Dong X, Deng J, Liao L, Liao Z, Yang H and He S: Isoquercitrin inhibits the progression of liver cancer <em>in vivo</em> and <em>in vitro</em> via the MAPK signalling pathway. Oncol Rep 31: 2377‑2384, 2014], suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source.<br />Given the errors that were identified in the compilation of Fig. 2 in this article, and the fact that all the data in this figure had been re‑used from a previously published source, the Editor of <em>Oncology Reports</em> has decided that this article should be retracted from the publication owing to a lack of overall confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience that might result from the retraction of this article. [Oncology Reports 33: 840‑848, 2015; DOI: 10.3892/or.2014.3626]
What problem does this paper attempt to address?